I. Introduction
===============

Gastric mucins consist primarily of heavily glycosylated glycoproteins that protect the gastric mucosa from the external environment by forming a mucous gel layer \[[@B24]\]. These mucins are classified into two subtypes: surface mucin and gland mucin. The former is secreted from surface mucous cells lining the gastric mucosa and contains surface mucin-specific glycans such as Lewis-related blood group carbohydrates attached to the mucin core protein MUC5AC, while the latter is secreted from gland mucous cells, including pyloric gland cells and mucous neck cells, located in the lower layer of the gastric mucosa and contains gland mucin-specific glycans attached to MUC6 \[[@B22]\].

To detect these glycans histochemically, the galactose oxidase-cold thionin Schiff (GOCTS) reaction, originally developed as the galactose oxidase-Schiff reaction \[[@B10], [@B26]\], is used to stain surface mucin-specific glycans a blue color. On the other hand, gland mucin-specific glycans, also called class III mucins, are identified as a brown stain by paradoxical Concanavalin A staining (PCS), which consists of oxidation, reduction, reaction with Concanavalin A, and visualization by horseradish peroxidase \[[@B11], [@B20]\]. Dual staining using GOCTS followed by PCS can localize both types of glycans on a single tissue section (Fig. [1](#F1){ref-type="fig"}) \[[@B23]\].

Ishihara *et al.* developed the monoclonal antibody HIK1083, which specifically reacts with *O*-glycans having terminal α1,4-linked *N*-acetylglucosamine residues (αGlcNAc) contained in the gland mucin \[[@B8]\]. By using that antibody it was also shown that αGlcNAc expression is limited to gland mucous cells and duodenal Brunner's glands (Fig. [2](#F2){ref-type="fig"}) \[[@B8], [@B18]\]. Because the expression pattern of αGlcNAc was identical to that of class III mucin (Fig. [2](#F2){ref-type="fig"}), it was suggested that class III mucin could be αGlcNAc itself \[[@B21]\]. Although αGlcNAc glycan is unique to gastric gland mucin, its biological function has remained unknown.

αGlcNAc biosynthesis is catalyzed by a concerted reaction of various glycosyltransferases acting on serine or threonine residues of scaffold proteins such as MUC6 (Fig. [3](#F3){ref-type="fig"}). In particular, α1,4-*N*-acetylglucosaminyltransferese (α4GnT), which transfers GlcNAc from UDP-GlcNAc to terminal β-galactose (βGal) residues present in *O*-glycans with an α1,4-linkage, is critical to form αGlcNAc \[[@B19]\]. To understand αGlcNAc function in gastric mucosa, we isolated cDNA encoding α4GnT by expression cloning \[[@B21]\]. Using α4GnT cDNA as a molecular tool, we then showed that αGlcNAc is a class III mucin itself and has dual roles in antagonizing gastric cancer. In this review, I first describe the isolation and expression of α4GnT in gastric mucosa, and then report recent advances, emphasizing primarily our own data, in understanding how αGlcNAc protects against gastric adenocarcinoma.

II. Molecular Cloning and Expression of α4GnT, the Enzyme Responsible for αGlcNAc Biosynthesis
==============================================================================================

Because molecular cloning of cDNA encoding α4GnT was critical for understanding the biological role of αGlcNAc, we obtained human α4GnT cDNA using an expression cloning strategy (Fig. [4](#F4){ref-type="fig"}) \[[@B21]\]. Briefly, COS-1 cells, which are originally negative for αGlcNAc, were co-transfected with a human stomach cDNA library constructed in the mammalian expression vector pcDNAI together with a cDNA encoding the membrane-bound sialoglycoprotein of leukocytes leukosialin (CD43) which contains 80 *O*-glycans in its extracellular domain \[[@B3]\]. Transfected cells were then screened using monoclonal antibodies specific for αGlcNAc, including HIK1083 \[[@B8]\], PGM36, and PGM37 \[[@B14]\]. Transfected cells recognized by any of these antibodies were enriched by fluorescence-activated cell sorting. Plasmid cDNAs were rescued from sorted cells and used to transform *E. coli* MC1061/P3 cells. As pcDNAI carries a *sup* F gene that corrects defects in both ampicillin- and tetracycline-resistance genes present in the P3 episome, transformed MC1061/P3 cells were resistant to both antibiotics, while MC1061/P3 cells transformed only by the leukosialin plasmid were resistant only to ampicillin. Thus, to identify plasmids derived from the cDNA library, cells were selected in the presence of ampicillin and tetracycline. Isolation of human α4GnT cDNA was achieved after several rounds of sib selection.

Our analysis indicated that α4GnT is a typical type II membrane protein of 340 amino acids and exhibiting a very short cytoplasmic *N*-terminal domain, a transmembrane domain and a large extracellular catalytic domain \[[@B21]\]. α4GnT showed significant homology to α1,4-galactosyltransferase (α4GalT, Gb3/CD77 synthase), with 35% overall sequence similarity at the amino acid level \[[@B13]\]. We then generated polyclonal antibodies against α4GnT, which we used to show that α4GnT is expressed in mucous cells that secrete αGlcNAc (Fig. [5](#F5){ref-type="fig"}) \[[@B27]\].

III. αGlcNAc Is Identical to Class III Mucin
============================================

Since the expression pattern of class III mucin as identified by PCS is identical to that of αGlcNAc (Fig. [2](#F2){ref-type="fig"}), we investigated a potential association between αGlcNAc and class III mucin \[[@B21]\]. To this end, we generated a line of human gastric adenocarcinoma cells (AGS) stably expressing αGlcNAc (AGS-α4GnT) by transfecting AGS cells negative for both αGlcNAc and class III mucin with α4GnT cDNA. When we stained AGS-α4GnT cells with PCS, we detected class III mucin, demonstrating that αGlcNAc actually is class III mucin (Fig. [6](#F6){ref-type="fig"}).

IV. αGlcNAc Acts as a Natural Antibiotic against *H. pylori* Infection
======================================================================

*Helicobacter pylori* (*H. pylori*) causes various gastric diseases, including chronic active gastritis, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) \[[@B25]\]. *H. pylori* largely colonizes the surface mucin and is rarely found in gland mucin (Fig. [7](#F7){ref-type="fig"}A) \[[@B5]\], suggesting that the presence of αGlcNAc protects against *H. pylori* infection. To test the hypothesis, we transfected Lec2 cells, a mutant CHO cell line defective in a sialic acid transporter and thus expressing core 1 *O*-glycans on the surface \[[@B2]\], with three expression vectors encoding C2GnT, α4GnT, and soluble CD43 (sCD43) to prepare recombinant sCD43 displaying αGlcNAc (Fig. [3](#F3){ref-type="fig"}) \[[@B12]\]. Lec2 cells are originally negative for core 2 branched structure and αGlcNAc. C2GnT forms a core 2 branched structure on core 1 structures \[[@B1]\]. β4GalT, expressed endogenously in Lec2 cells, attaches βGal to the core 2 branched structure, and α4GnT finally attaches GlcNAc to the terminal ends of core 2 and core 1 *O*-glycans with an α1,4-linkage. As controls, we transfected Lec2 cells with only two vectors, C2GnT and sCD43, allowing synthesis of *O*-glycans lacking αGlcNAc. After concentration of sCD43 released into culture medium of transfected Lec2 cells, we cultured *H. pylori* with varying amounts of sCD43 carrying αGlcNAc and found that *H. pylori* growth and motility were significantly suppressed in a dose-dependent manner and bacteria showed abnormal morphology, such as elongation and bending (Fig. [7](#F7){ref-type="fig"}B, [7](#F7){ref-type="fig"}C). By contrast, when we incubated bacteria with control sCD43 lacking αGlcNAc, we did not observe these effects, indicating that αGlcNAc antagonizes *H. pylori*growth \[[@B12]\].

Hirai *et al.* had previously demonstrated that the *H. pylori* cell wall contains a unique glycolipid, cholesteryl-α-[d]{.smallcaps}-glucopyranoside (CGL) \[[@B6]\]. To determine how αGlcNAc antagonized *H. pylori*growth, we cloned cholesterol α-glucosyltransferase (αCgT) from *H. pylori* \[[@B15]\] and then demonstrated that αGlcNAc suppressed its ability to form CGL *in vitro*\[[@B16]\]. We also showed that an active form of αCgT is present in the membrane fraction of bacteria, suggesting that bacterial αCgT is likely accessible to αGlcNAc in gland mucin \[[@B7]\].

*H. pylori* requires exogenous cholesterol for CGL biosynthesis. Thus, we cultured *H. pylori* in the absence of cholesterol and found that resultant *H. pylori* lacking CGL exhibited reduced growth and motility, and died completely upon prolonged incubation up to 21 days, indicating that CGL is indispensable for *H. pylori* survival \[[@B12]\]. Taken together, these studies show that αGlcNAc inhibits CGL biosynthesis by *H. pylori* by suppressing αCgT, thus protecting the gastric mucosa from infection. Notably*,*a single nucleotide polymorphism of the *A4GNT*gene associated withhigher risk for *H. pylori* infection was reported by Zheng *et al*. \[[@B28]\].

V. αGlcNAc Serves as a Tumor Suppressor for Differentiated-type Adenocarcinoma of the Stomach
=============================================================================================

We next asked whether αGlcNAc had additional protective activities. To do so, we generated mice deficient in α4GnT by disrupting the *A4gnt* gene \[[@B9]\]. Immunohistochemistry using the αGlcNAc-specific antibody HIK1083 revealed that *A4gnt*-deficient mice showed a complete lack of αGlcNAc expression in gastric gland mucin and duodenal Brunner's gland (Fig. [8](#F8){ref-type="fig"}). In addition, MALDI-TOF-MS analysis demonstrated that unlike wild-type mice, the gastric mucin of *A4gnt*-deficient mice showed a complete absence of *O*-glycans carrying αGlcNAc in oligosaccharides. These results formally establish that α4GnT is the sole enzyme catalyzing addition of αGlcNAc to *O*-glycans *in vivo* \[[@B9]\]*.* Histopathology analysis of gastric tissues from *A4gnt*-deficient mice revealed that they spontaneously exhibited hyperplasia by 5 weeks of age, low-grade dysplasia by 10 weeks, and high-grade dysplasia by 20 weeks. In 30-week-old mice, differentiated-type adenocarcinoma developed in 2 of 6 *A4gnt*-deficient mice, and the incidence of adenocarcinoma increased by 50 weeks of age. All 50-week-old mice exhibited differentiated type adenocarcinoma, with cancer cells located primarily in the gastric mucosa, and up to 60 weeks of age mice showed no sign of distant metastasis (Fig. [9](#F9){ref-type="fig"}). These pathologies were consistently restricted to the antrum of the glandular stomach, indicating that the mucous neck cells in the fundic mucosa were not involved in the gastric tumorigenesis in this model. Interestingly, mutant mice did not show gastric undifferentiated-type adenocarcinoma, such as signet ring cell carcinoma, clearly demonstrating that *A4gnt*-deficient mice develop gastric differentiated-type adenocarcinoma through a hyperplasia-dysplasia-carcinoma sequence, even in the absence of *H. pylori* infection. No significant abnormalities were found in organs other than the glandular stomach. These results indicate that αGlcNAc serves as a tumor suppressor for gastric adenocarcinoma. In fact, significant reduced levels of αGlcNAc relative to MUC6 are seen in human early gastric differentiated-type adeno-carcinoma, and 40% of 48 MUC6-positive gastric cancer patients were completely negative for αGlcNAc (Fig. [10](#F10){ref-type="fig"}) \[[@B9]\]. Significant reduction of αGlcNAc was also seen in a potentially premalignant lesion gastric tubular adenoma.

To define pathways linking αGlcNAc to tumor suppression, we carried out microarray and quantitative RT-PCR analyses of gastric mucosa from *A4gnt*--deficient and wild-type mice. Genes encoding inflammatory chemokine ligands such as Ccl2, Cxcl1, and Cxcl5, proinflammatory cytokines such as Il-11 and Il-1β, and growth factors such as Hgf and Fgf7 were upregulated in the gastric mucosa of mutant mice. Ccl2 upregulation is of particular interest, as it attracts tumor-associated macrophages, which exert pro-tumorigenic immune responses and promote tumor angiogenesis \[[@B4], [@B17]\]. In fact, both infiltration of inflammatory cells such as mononuclear cells and neutrophils and angiogenesis increased progressively in the gastric mucosa of *A4gnt*--deficient mice as they aged. These results demonstrate that αGlcNAc loss triggers gastric carcinogenesis through inflammation-associated pathways *in vivo*.

VI. Conclusion
==============

In this review, I conclude that gastric gland mucin-specific αGlcNAc is identical to class III mucin detected by PCS and plays a dual role: it acts as a natural antibiotic to prevent gastric cancer by inhibiting *H. pylori* infection and it also functions as a tumor suppressor for differentiated-type gastric adenocarcinoma. These studies should encourage future development of new strategies to detect, diagnose, treat, and prevent gastric cancer.

Part of this review article was presented at the 54th Annual meeting of the Japan Society of Histochemistry and Cytochemistry in Tokyo on September 27--28, 2013, as the Takamatsu Prize Lecture. I am grateful to all collaborators for their contributions to this research. I also wish to thank Dr. Tsutomu Katsuyama, Emeritus Professor of Shinshu University, Dr. Minoru Fukuda, Professor at the Sanford-Burnham Medical Research Institute, and Dr. Michiko N. Fukuda, Professor at the Sanford-Burnham Medical Research Institute, for their encouragement and collaboration, and Dr. Elise Lamar for editing this manuscript.

![Histochemical demonstration of the surface mucin- and gland mucin-specifc glycans in human stomach, as revealed by GOCTS-PCS staining. Glycans in the surface mucin are detected by the GOCTS reaction as a blue color, while glycans in gland mucin appear brown following PCS staining. HE, Hematoxylin & Eosin. Bars=200 µm.](AHC13034f01){#F1}

![Comparison of αGlcNAc and class III mucin in human gastrointestinal tract. Expression of αGlcNAc in the gastrointestinal tract mirrors that of class III mucin. αGlcNAc panels: immunohistochemistry with HIK1083 antibody. Class III mucin panels: paradoxical Concanavalin A staining. Bar=200 µm, and bar in inset indicates 20 µm. (from Nakayama *et al.* 1999; Copyright 1999 National Academy of Sciences, USA)](AHC13034f02){#F2}

![αGlcNAc biosynthesis. αGlcNAc is synthesized by a concerted reaction of various glycosyltransferases. α4GnT, which transfers GlcNAc from UDP-GlcNAc to βGal residues attached to serine/threonine residues present in *O*-glycans with an α1,4-linkage, plays a key role to form αGlcNAc. UDP, uridine diphosphate. ppGalNAcT, polypeptide *N*-acetylgalactosaminyltransferase. β3GalT, β1,3-galactosyltransferase. C2GnT, core 2 β1,6-*N*-acetylglucosaminyltransferase. β4GalT, β1,4-galactosyltransferase. α4GnT, α1,4-*N*-acetylglucosaminyltransferase.](AHC13034f03){#F3}

![Expression cloning strategy used to obtain α4GnT cDNA. See text for detail.](AHC13034f04){#F4}

![Expression of αGlcNAc and α4GnT in human gastric mucosa. (**A**) αGlcNAc is expressed in gland mucin secreted from the pyloric gland. (**B**) α4GnT is detected in the supranuclear region, which corresponds to the Golgi apparatus of the pyloric gland cells. (**C**) αGlcNAc is expressed in the medial Golgi of mucous neck cells of the fundic gland. **A:** Immunohistochemistry with HIK1083 antibody. **B** and **C**: Immunohistochemistry with anti-α4GnT antibody. Bars=200 µm (**B**) and 50 µm (**B**, inset), respectively. Bar=500 nm (**C**). (**C** is from Zhang *et al.* 2001; doi: 10.1177/002215540104900505 on SAGE Journals)](AHC13034f05){#F5}

![Expression of class III mucin on gastric adenocarcinoma AGS cells stably transfected with α4GnT cDNA. AGS-α4GnT cells express αGlcNAc and are positive for class III mucin. AGS-mock cells, transfected by vector alone, are negative for both αGlcNAc and class III mucin. αGlcNAc is detected by immunocytochemistry with HIK1083 antibody, and class III mucin is detected by paradoxical Concanavalin A staining. Bar=50 µm. (from Nakayama *et al.* 1999; Copyright 1999 National Academy of Sciences, USA)](AHC13034f06){#F6}

![Antimicrobial activity of αGlcNAc against *H. pylori* infection. (**A**) Chronic active gastritis of human gastric mucosa caused by *H. pylori*infection. The microbe is rarely found in the gland mucin expressing αGlcNAc. Left panel shows Hematoxylin & Eosin staining, and right panel shows immunofluorecent staining using anti-*H. pylori* antibody (as a green color) and HIK1083 antibody for αGlcNAc (as a red color). Bar=100 µm. (**B**) Growth curves of *H. pylori* cultured in the presence of sCD43 carrying αGlcNAc (αGlcNAc (+)) or sCD43 lacking αGlcNAc (αGlcNAc (--)). One milliunit of αGlcNAc (+) corresponds to 1 µg of GlcNAcα-*p*NP. A600: absorbance at 600 nm. (**C**) Scanning electron micrographs showing *H. pylori*incubated with 31.2 mU/ml of sCD43 carrying αGlcNAc (αGlcNAc (+)) or the same protein concentration of sCD43 lacking αGlcNAc (αGlcNAc (--)) for 3 days. Bar=1 µm. (Panels **B** and **C** from Kawakubo *et al.* 2004; Copyright 2004 American Association for the Advancement of Science)](AHC13034f07){#F7}

![Loss of αGlcNAc in *A4gnt*-deficient mice. αGlcNAc is completely absent in gland mucous cells of the gastric mucosa and in Brunner's glands of the duodenal mucosa of *A4gnt*-deficient mouse (*A4gnt*^--/--^*)*. Shown is immunohistochemistry of one-week-old mice with αGlcNAc-specific HIK1083 antibody. Bar=100 µm.](AHC13034f08){#F8}

![Gastric pathology of *A4gnt*-deficient mice. Representative histopathology analysis showing hyperplasia at 5 weeks (upper right), high-grade dysplasia at 20 weeks (lower left), and differentiated type adenocarcinoma at 50 weeks (lower right) in the pyloric mucosa of *A4gnt*-deficient mice. For comparison (upper left), pyloric mucosa from a 5-week-old wild-type mouse is shown. Bar=100 µm.](AHC13034f09){#F9}

![Human early gastric differentiated-type adenocarcinoma. No expression of αGlcNAc is seen in MUC6-positive adenocarcinoma cells. Normal pyloric glands (\*) adjacent to the carcinoma cells are positive for both αGlcNAc and MUC6. HE, Hematoxylin & Eosin. αGlcNAc and MUC6 are detected by immunocytochemistry with HIK1083 and anti-MUC6 (clone CLH5) antibodies, respectively. Bar=100 µm.](AHC13034f10){#F10}
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